Get ready for a trip to the emergency
room if you take this drug inappropriately. Also, keep this drug out
of reach of children of any age less than 18. These warnings are
necessary and very wise for a neuropathy pain drug just approved for
use by the FDA.
Other warnings can be found here and
need to be taken seriously. For me, this will be one medication I
will avoid if at all possible – FDA approval not withstanding.
There are just too many potential risk hazards for me to be
comfortable using this. The fact that this medication has to be
doctor monitored so closely because of potential of addiction is
another factor in my avoiding this medication.
The US Food and Drug Administration
has approved US sales of NUCYNTA® ER (tapentadol), a twice-daily
extended-release oral analgesic for the treatment of pain from
diabetic peripheral neuropathy. The drug, produced by New
Jersey-based Janssen Pharmaceuticals, Inc., provides around-the-clock
management for moderate to severe chronic neuropathic pain. Janssen
says that it is currently the only opioid on the
US market that has been approved for treating the condition.
I will continue to suffer with what I
considerate moderate chronic neuropathy pain rather that use this
medication. I will continue to use gabapentin, which alleviates some
of the pain and is not a narcotic.
While this medication may work for some
people, after reading the warnings accompanying the press release and
then the FDA link above, it is not a medication I wish to consider.
This medication also has great potential for being abused like other
controlled substances.
No comments:
Post a Comment